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Abstract
Background: There are several open scientific questions regarding the optimal antibiotic treatment of spinal
infections (SIs) with or without an implant. The duration of postsurgical antibiotic therapy is debated.
Methods: We will perform two unblinded randomized controlled trials (RCTs). We hypothesize that shorter
durations of systemic antibiotic therapy after surgery for SI are noninferior (10% margin, 80% power, α = 5%) to
existing (long) treatment durations. The RCTs allocate the participants to two arms of 2 × 59 episodes each: 3 vs. 6
weeks of targeted postsurgical systemic antibiotic therapy for implant-free SIs or 6 vs. 12 weeks for implant-related
SIs. This equals a total of 236 adult SI episodes (randomization scheme 1:1) with a minimal follow-up of 12 months.
All participants receive concomitant multidisciplinary surgical, re-educational, internist, and infectious disease care.
We will perform three interim analyses that are evaluated, in a blinded analysis, by an independent study data
monitoring committee. Besides the primary outcome of remission, we will also assess adverse events of antibiotic
therapy, changes of the patient’s nutritional status, the influence of immune suppression, total costs, functional
scores, and the timely evolution of the (surgical) wounds. We define infection as the presence of local signs of
inflammation (pus, wound discharge, calor, and rubor) together with microbiological evidence of the same
pathogen(s) in at least two intraoperative samples, and we define remission as the absence of clinical, laboratory,
and/or radiological evidence of (former or new) infection.
Discussion: Provided that there is adequate surgical debridement, both RCTs will potentially enable prescription of
less antibiotics during the therapy of SI, with potentially less adverse events and reduced overall costs.
Trial registration: ClinicalTrials.gov, NCT04048304. Registered on 5 August 2019.
Protocol version: 2, 5 July 2019.
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Background
Surgical site infections are feared complications of spinal
surgery, the volume of which is expected to increase
every year worldwide [1]. Likewise, community-acquired
spinal infections (SIs) are associated with increased mor-
bidity and costs and prolonged hospital stay for the pa-
tients [1]. Most scientific papers are interested in the
epidemiology of SI and risk factors for surgical site infec-
tions after spinal surgery [2], occurring at 1–3% [2–4],
rather than the modalities and outcomes of treatment.
Risk factors leading to infection may be multiple. To cite
an example, according to our University Spine Center at
the Balgrist University Hospital in Zurich, associated risk
factors are a high serum creatinine level, blood loss, or
steroid use. Some of these risk factors influence the oc-
currence of infection only indirectly and act as a con-
founding element. For example, fusion surgery,
particularly if it involves the lumbosacral spine, and
length of surgery are associated with high blood loss [2],
which itself may become an independent risk factor for
infection. This remains the domain of infection control.
In contrast, we are interested if we can streamline anti-
biotic therapy after the occurrence of infection, especially
by shortening its duration. Such results can be of high
value for clinicians. So far, the literature on antibiotic regi-
mens in SI is very sparse and strongly eminence-based (in-
stead of being based on evidence). Most experts
recommend a minimum (intravenous) antibiotic course
duration of 2–4 weeks, often followed by prolonged oral
antimicrobial regimens in case of infected osteosynthesis
material that was kept in place [1]. Comparative data sup-
porting these individual therapeutic recommendations are
lacking. Indeed, one coauthor of the current project ana-
lyzed long-term remission with an emphasis on surgical
and antibiotic-related parameters. The patients had a me-
dian of two surgical debridements with a median duration
of antibiotic therapy of 8 weeks, during which the therapy
was delivered parenterally for 2 weeks. In 53 cases (80%),
the episodes were in complete remission. In cluster-
controlled multivariate Cox regression analysis adjusting
for the case mix, the duration of postsurgical antibiotic
therapy was completely indecisive regarding the “remis-
sion of infection” or “mechanical sequelae” [1]. Especially,
the following clinically important variables were all unre-
lated to remission: number of surgical interventions (haz-
ard ratio [HR], 0.9; 95% confidence interval, 0.8–1.1),
infection due to Staphylococcus aureus (HR, 0.9; 0.8–1.1),
infection due to local antibiotic therapy (HR, 1.2; 0.6–2.4),
and duration of total (HR, 1.0; 0.99–1.01) or just paren-
teral (HR, 1.0; 0.99–1.01) antibiotic use [1].
If there is no benefit to long duration antibiotic ther-
apy, it would be important to limit the use of antibiotic
agents to avoid furthering the problem of antibiotic re-
sistance and adverse events, because the incidence of
adverse events related to antibiotic therapy (substantial
adverse events in up to 29% of all treatment episodes
[5]) and costs genuinely increase with longer duration of
antimicrobial administration [5]. We equally think that
as long as oral antibiotics are used with good bioavail-
ability and bone tissue diffusion, the antimicrobial treat-
ment can be considerably shortened for the benefit of
patients and the healthcare sector [6].
Methods
Setting
The Balgrist University Hospital (incorporating the Univer-
sity Spine Center Zürich) is a tertiary referral center for SI
that is affiliated with the University of Zurich, Switzerland.
Regarding SIs, it has a multidisciplinary team composed of
five spine surgeons (both orthopedic and neurosurgery),
three internist physicians, a hospital pharmacist, specialized
wound nurses, musculoskeletal expert radiologists, three
specialized nutritionist nurses, two to four dedicated phys-
iotherapists, and up to four infectious disease physicians
who specialize in orthopedic infections. Moreover, this
team is supported by a research campus (Balgrist campus)
with biobanking facilities and a Unit for Clinical and Ap-
plied Research with nine study nurses and two personnel
with experience in biostatistics and investigational designs
(www.balgrist.ch). Our study starts at Balgrist but is ex-
pandable to other national or international centers with ex-
perience in the treatment of SIs.
Study objectives
We plan a prospective randomized study of SIs for
which intraoperative debridement is part of the therapy.
The primary study objective is to evaluate if 6 weeks of
systemic and targeted antibiotic therapy postoperatively
is not inferior to 12 weeks (noninferiority trial) in cases
of infection in spinal implant-associated infections when
spine implants are left in place. For SIs without implants,
this objective is the evaluation of whether 3 weeks of
antibiotic therapy is not inferior to 6 weeks in postopera-
tive SIs without an implant. The switch from intraven-
ous to oral medication will occur early, in the absence of
sepsis sensu strictu, bacteremia, or intestinal problems,
at the latest after 1 week of treatment. Secondary objec-
tives are assessments of differences in total costs, sick
leave, adverse events, mechanical sequelae, handicap at 6
and 12 months after treatment, and changes in nutritional
status during therapy. A third objective is the assessment
of infected tissue/bone for future studies (Biobanking).
Finally, our study includes the evaluation of the nutri-
tional status of the patient at the beginning and the end
of SI treatment. Instead of throwing tissue/bone away,
we will collect intraoperative tissue and/or vertebral
bone for other studies. Of note, biobanking and partici-
pation in the clinical trial are exclusive of each other.
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Patients refusing to provide intraoperative tissue for bio-
banking still have the choice to participate in the ran-
domized study and vice versa.
Definitions and eligibility criteria for participants
SI is defined as having at least two local manifestations
of inflammation (swelling or induration, erythema, local
tenderness or pain, local warmth, purulent discharge) to-
gether with the same pathogen(s) retrieved in the micro-
biological culture of at least two intraoperative samples
in antibiotic-naive cases. Systemic inflammation (fever,
shivering, bacteremia, hemodynamic alterations) or
histological confirmation is considered facultative. Re-
mission is defined as the absence of any clinical, anam-
nestic, radiological, or laboratory signs of former (or
new) SI during 12months of follow-up. A diagnostic
control puncture for the microbiological exclusion of
dormant bacteria is not necessary. Of note, internal
closed fractures and residual back pain can be inter-
preted as remission as long there are no signs of infec-
tion as defined. Figure 1 displays the inclusion/exclusion
criteria, and Fig. 2 shows the study flowchart.
Interventions and study conduct
Upon individual consent of the patient, we will collect
clinical, radiological, nutritional, and laboratory data
from each SI episode. The biobank will store intraopera-
tive specimens in the Balgrist campus for 10 years.
Table 1 reveals the variables of interest that we will col-
lect during the trials. The two randomized controlled tri-
als (RCTs) depend on the presence or absence of
infected osteosynthesis material:
 Infected spine material that was not entirely removed
(or new material inserted): Randomization between 6
and 12 weeks (± 4 days) of total antibiotic therapy
counted since the first debridement for infection;
early switch to oral targeted therapy
 Infected spine without residual material:
Randomization between 3 and 6 weeks (± 4 days) of
total antibiotic therapy counted since the first
debridement for infection; early switch to oral
targeted therapy
After randomization, the study participants will be ac-
tively followed for 12months. At database closure, we will
review the medical charts of all patients to seek unsched-
uled visits since inclusion. This “passive follow-up” can
reach up to 4 years and terminates at the date of database
closure. The scheduled study visits take place as follows:
visit 1, enrollment (day 1); visit 2, day 15 (± 5 days); visit 3,
day 21 (± 5 days); visit 4, day 42 (± 5 days); visit 5, day 84
(± 5 days); end of treatment visit 6, day 21, 42, or 84 (± 5
Fig. 1 Study criteria
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days) (only if still receiving treatment after visit 4); test-of-
cure visit, approximately (± 60 days) at 12months (visit 7).
The Standard Protocol Items: Recommendations for
Interventional Trials (SPIRIT) diagram in Fig. 3 shows the
timely assessments that are identical for both RCTs.
Antibiotic agents
The antibiotic therapy is prescribed by infectious disease
physicians with experience in orthopedic infections, the
surgeons in charge of the patient, and/or the internists. It
is administered by nurses experienced in orthopedic infec-
tions. Initially, antibiotic therapy is either empiric or tar-
geted to the results of preoperative bone biopsy. After 2–5
days, antibiotic therapy becomes targeted to the pathogens
identified in microbiological cultures and their antibiotic
susceptibility profile. The choice of the agent and its intra-
venous or oral administration route are usually at the dis-
cretion of the infectious disease physician. However, for
this study, and in order to achieve minimal homogeneity,
we established a list of “allowed antibiotics” and their rec-
ommended doses (Table 2). The investigators must choose
from among them, unless the causing pathogen of the SI is
not listed in Table 1 or if an additional surgical site infec-
tion (e.g., postoperative pneumonia) necessitates a broad-
spectrum antibiotic treatment. Of note, in this study, we
will not test special doses or new indications for antibiotic
therapy. Only the duration of the therapy will be deter-
mined. All antibiotics are already on the Swiss market and
approved by Swissmedic, the corresponding authority for
medication use. We avoid placebos, topical antibiotics, and
Fig. 2 Study flowchart
Table 1 Prospectively assessed variables
Patients’ general descriptive characteristics: age, sex, body mass index,
comorbidities, anticoagulation, known immunosuppression (diabetes
mellitus, renal dialysis, cirrhosis, pregnancy, iatrogenic
immunosuppression, untreated human immunodeficiency virus [HIV]
infection, agranulocytosis, active cancer), American Society of
Anesthesiologists (ASA) physical status classification, Nutritional Risk
Screening (NRS 2002), neck disability index (NDI), or Oswestry low back
disability index (ODI)
Patients’ spine surgery-specific baseline data: number and type of
surgeries for the actual problem; agent, dose, and duration of
presurgical antibiotic therapy; agent and duration of perioperative
prophylaxis during debridement; cell count (absolute number and
percentage of leukocytes); initial serum C-reactive protein (CRP) level;
presence of initial bacteremia; presence of vertebral osteomyelitis; and
presence and type spinal implants. Spine surgery data: anatomical
localization of surgery, type of surgery, microbiological results, and hist-
ology (if applicable)
Treatment and outcome: number of surgeries to treat infection; total
duration of antibiotic therapy; duration, agent, and dose of intravenous
and oral antibiotic therapy; intraoperative vancomycin powder; wound-
healing problems; presence and duration of vacuum-assisted negative
pressure therapy; adverse events; clinical or and microbiological recur-
rence; date and reasons for rehospitalization and retreatment; follow-up
data; fatalities; Nutritional Risk Screening (NRS 2002); neck disability index
(NDI); or Oswestry low back disability index (ODI)
Administrative data: total hospitalization and outpatient costs, duration
of hospital stay, duration of sick leave, duration of inpatient
rehabilitation
One or two intraoperative bone and soft tissue samples for the
biobank at Balgrist campus
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Fig. 3 Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) chart of the enrollments and assessments during both
randomized controlled trials
Table 2 List of allowed antibiotic treatments (empirical or targeted)
Antibiotic agent Allowed dosing regimens Allowed total daily dosea
Levofloxacin by mouth 500mg every 12 h 750 to 1000 mg
Ciprofloxacin by mouth 500mg every 12 h 750 to 1500 mg
Amoxicillin/clavulanate by mouth 500/125mg every 12 h or every 8 h 1000/250mg to 1500/375mg
Amoxicillin/clavulanate intravenous 1000/200mg every 12 h or every 8 h 2000/400mg to 3000/600mg
Cefuroxime intravenous 1500mg every 8 h 4500 mg
Ceftriaxone intravenous 2000mg every 24 h 2000 mg
Co-trimoxazole by mouth 960mg every 12 h or every 8 h 1920 to 2880 mg
Clindamycin by mouth 300 or 450 mg every 6 h 1200 to 1800 mg
Doxycycline by mouth 100mg every 12 h 200mg
Linezolid by mouth 600mg every 12 h 1200 mg
Linezolid intravenous 600mg every 12 h 1200 mg
Metronidazole by mouth 500mg every 8 h or 500 mg every 6 h 1200 to 2000 mg
Metronidazole intravenous 500mg every 8 h or every 6 h 1500 to 2000 mg
Vancomycin intravenous 15 mg/kg every 12 h Target serum levels, 10–20mg/L
Meropenem intravenous 1 or 2 g every 12 h or every 8 h 2 to 6 g
Piperacillin/tazobactam intravenous 4000/500mg every 8 h 1200/1500mg (12 g/1.5 g)
aTo be adapted to renal insufficiency
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topical antiseptics, except for the preincisional skin prepar-
ation and (potential) use. Anesthesiologists and surgeons
are also free to comply with the prevention protocols, even
if the patient is already infected, by administering the
standard antibiotic prophylaxis (cefuroxime, vancomycin,
or clindamycin) for up to three consecutive doses.
Pregnancy and breastfeeding
This cohort, including all antibiotics and surgeries, has
no specific relationship to pregnant or breastfeeding
women and their children. Additionally, the study popu-
lation is likely not to include women of childbearing age.
Thus, pregnant and breastfeeding women are not ex-
cluded. The investigators will avoid agents that are not
allowed for pregnant or breastfeeding women according
to the Swiss Compendium (www.compendium.ch).
Outcomes of interest
For the RCTs and biobanking, we will collect data and
biological material. Concerning the RCTs, Table 1 (bot-
tom) summarizes the outcome parameters. Regarding the
investigation of dynamic changes in nutritional status dur-
ing SI care, specialist nutrition nurses will assess the status
at baseline and the end of treatment. In case of severe
malnutrition, they are allowed to propose corrective mea-
sures already during the SI therapy because it would be
unethical not to intervene only for study purposes. Finally,
the database will be sufficiently large to estimate the influ-
ence of an underlying chronic immune suppression (i.e.,
diabetes mellitus, chronic steroid therapy, dialysis, un-
treated human immunodeficiency virus, active cancer in
therapeutic or palliative treatment, CHILD C) on SI out-
comes and related nutritional status. We also remind the
reader that patients with very severe iatrogenic immune
suppression, such as recent solid organ or bone transplant
in the last 5 years, are exempted from SASI (Short Antibi-
otics for Spine Infections) trials (Fig. 1).
Allocation and timetable
After written informed consent forms are given to partici-
pants (until day 5 of debridement), the unblinded
allocation occurs electronically with a randomization
scheme of 1:1 (randomization without blocked or matched
variables). The study nurse of the Unit for Clinical and
Applied Research and/or the coinvestigators will imple-
ment the allocation sequence in the trial. For both RCTs,
we need 36months of study time, starting from August
2019. Table 3 highlights some key time point events.
Statistical analyses and sample size
Both RCTs are noninferiority trials. Remission incidence
(at the first attempt of therapy) is set at 5% (5% recur-
rence in both arms). The maximum clinically acceptable
difference (unidirectional noninferiority margin with
binary outcome categorical variables) is arbitrarily fixed
at 10% regarding the primary outcome of remission [1].
Assuming a risk of α = 0.05 and a power of 80%, it will
be necessary to recruit 59 patients in each antibiotic
duration arm (short or long). Together with the distinc-
tion of the RCTs as studies of implant-related and
implant-free SIs, we will finally need 2 × 2 × 59 episodes,
equaling a total of 236 SI episodes within 3 years. For as-
sessment of the formal noninferiority requirement (re-
garding the primary outcome of remission), we will
compute with a unidirectional P value limit of 0.025. We
do not predefine a noninferiority margin for secondary
outcomes such as costs, adverse events, functional out-
comes, underlying immune suppression, dynamic
changes in the nutrition status, and biobanking.
Interim analyses
When the first 20 episodes of any randomization branch
will have complete follow-up, and again at 60 and 120 SI
episodes, we will perform three interim analyses. On this
occasion, we will equally check if the expected statistical
power for the final analysis will be acceptable. If it is less
than 30%, we will consider that the trial will not be able to
demonstrate the result, and the recruitment will no longer
be ethical. The most frequent conditional power evaluated
under the current trend (i.e., using the information from
the collected data) will be assessed [7, 8]. The study data
monitoring committee will consist of independent
Table 3 Timetable of the study
Activity 2019 2020 2021 2022
P S A W P S A W P S A W P S A W
Permission from ethics committees
Ongoing recruitment of new sites
Clinical study
Database
Interim statistical analysis
Final statistical analyses
Writing up of results and manuscript
Abbreviations: P spring, S summer, A autumn, W winter
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surgeons or physicians with clinical and statistical experi-
ence who are not participating in the study. They will de-
cide about the future of the trial, entirely or partially, after
each of the three interim analyses. The principal investiga-
tor (PI) and the sponsor will present the data in a blinded
form to the data monitoring committee. The committee
members will only know if there is an implant, but they
will ignore allocations to the antibiotic arms.
The intention-to-treat (ITT) population will consist of
all randomized patients who have signed the consent for
the participation. Patients will be analyzed according to
treatment group assignment, regardless of whether they
receive any treatment or the wrong treatment or are lost
to follow-up. The per-protocol (PP) population will con-
sist of all patients who complete the study and who have
not deviated significantly from the protocol. The statis-
tical analyses will mostly be based on descriptive
analyses; group comparisons; and a multivariate, un-
matched, eventually cluster-controlled Cox regression
analysis adjusting for the large case mix that we expect.
Equally, a generalized estimating equation model might
adjust for clustering in case of multicenter origin of the
patients. The biostatistician will analyze the datasets in a
blinded form (as group A or B), but the PI, the study
nurses, and the sponsor will ultimately unblind the allo-
cations for data verification and definition of the ITT
and PP populations.
Ethical and regulatory aspects
Study registration, ethical conduct, and categorization
The study is approved by the Ethical Committee of Zurich
(no. 2019-00646) and registered in the Swiss Federal
Complementary Database (portal) and in the Clinical-
Trials.gov international trial registry (NCT04048304). This
study only makes use of the medicinal products and anti-
biotic agents that are already authorized in Switzerland.
The indication and the dosage are used in accordance
with the prescribing information and the international
guidelines, making this study fall into the category of Clin-
ical Trials A. The study will be carried out in accordance
to the protocol and with principles enunciated in the
Helsinki declaration, good clinical practice guidelines, and
Swiss law. The ethical committee receives annual safety
reports and is informed about the study stop/end. Sub-
stantial amendments are only implemented after a new
ethical committee approval.
Patient information and informed consent
Participants will be recruited by any of the investigators
of the study. Our institution has a standardized proced-
ure for recruiting participants because participant stud-
ies are common. Each participant will be informed that
participation in the study is completely voluntary and
that he/she may withdraw from the study at any time
and that withdrawal of consent will not affect his/her
medical assistance and treatment in the future. All par-
ticipants of the study will be provided a participant in-
formation sheet and informed consent form entailing
sufficient information. For the biobank, the participants
will sign the general consent for the further use of per-
sonal data and biologic material. The investigators affirm
and uphold the principle of the participant’s right to
privacy and that they shall comply with applicable priv-
acy laws and/or the corresponding section of the study-
specific consent.
Safety issues
Monitoring
The Unit for Clinical and Applied Research of Balgrist
University Hospital will assign an independent monitor.
Regular monitoring visits at the investigator’s site prior
to the start and twice during the course of the study will
help us to follow the participants’ progress, to assure ut-
most accuracy of the data, and to detect possible errors
at an early time point. The monitor will review all or a
part of the case report forms (CRF) and written in-
formed consent forms. The accuracy of the data will be
verified by reviewing the above-referenced documents.
There will be a close-out visit at the study end. During
the monitoring, all documents, including source data/
documents, will be accessible to the monitor.
Audits and inspections
An audit/inspection of this study may be conducted by
the competent authority. The quality assurance auditor/
inspector can have access to all medical records, the in-
vestigator’s study-related files and correspondence, and
the informed consent documentation that is relevant to
this clinical study. The investigator will allow the per-
sons responsible for the audit or the inspection to have
access to the source data/documents and to answer any
questions that arise. All involved parties will keep the
patient data strictly confidential.
Early termination of the study (participation)
The investigators may terminate the study prematurely
according to certain circumstances, such as for ethical
concerns, insufficient participant recruitment, when the
safety of the participants is doubtful or at risk, alter-
ations in accepted clinical practice that make the con-
tinuation of a clinical trial unwise, and early evidence of
benefit or harm of the experimental intervention. If a pa-
tient is withdrawn, the reason will be noted. When pos-
sible, evaluations required at the next scheduled visit
will be performed at early termination.
Betz et al. Trials          (2020) 21:144 Page 7 of 11
Treatment by specialists
All surgeries will be performed with the supervision and
participation of an experienced spine surgeon. The anti-
biotic therapy is ordered and supervised by internists
and infectious disease physicians with therapeutic and
academic experience in SI treatments. The current med-
ications of the study patients, as well as possible interac-
tions, will be controlled by the internists several times
per week during hospitalization.
Definition and assessment of (serious) adverse events and
other safety-related events
An adverse event is any untoward medical occurrence in a
patient and does not necessarily have a causal relationship
with the study procedure. A serious adverse event (SAE) is
classified as any untoward medical occurrence that results
in death, is life-threatening, requires inpatient
hospitalization or prolongation of existing hospitalization,
and/or results in persistent or significant disability/incap-
acity. In addition, important medical events that may not
be immediately life-threatening or result in death but may
jeopardize the patient or may require intervention to pre-
vent one of the other outcomes listed above should also
usually be considered serious. Participants with ongoing
SAEs at study termination will be further followed up
until recovery or until stabilization of the disease after ter-
mination. The investigators will make a causality assess-
ment of the event for the study. All SAEs must be
reported immediately and within a maximum of 24 h to
the sponsor-investigator of the study. SAEs resulting in
death are reported to the local ethics committee (via local
investigator) within 7 days. Patients who have experienced
adverse events and are leaving the study will be treated
off-study, without restriction, at the study site.
Case report forms, procedure of data analysis, and biobank
archiving
An electronic CRF will be generated for every patient.
All relevant study data are recorded by authorized per-
sons using the REDCap® electronic data capture tool [9]
and archived for a minimum of 10 years. Participating
patients will be registered in an enrollment log assigning
the participant to his/her study identifier. Corrections
can be made only by authorized persons. For data ana-
lysis, subject-related data from REDCap will be exported
and analyzed in statistical software (IBM SPSS Statistics
and/or Stata). Before data export, all patient identifiers
will be removed. Patient source and biobank data will be
registered using subject identifiers. Collection, disclos-
ure, and storage of patient-related data are carried out in
accordance with Swiss data protection regulations and
the Human Research Act. The biobank will store the in-
traoperative tissue samples in accordance with its guide-
lines (in RNALater at below-zero temperature (-20°C) in
the Balgrist Campus. Likewise, radiological data are
stored in the picture archiving and communication sys-
tem according to the standard at the Balgrist University
Hospital.
Theoretical risk of the study
Besides the retrospective identification of patients, we do
not see any particular risk for the patients regarding the
cohort. For biobanking specifically, a theoretical add-
itional risk could be the detection of unknown patholo-
gies if there would be further workup of the
intraoperative samples. Concerning the RCTs, a theoret-
ical risk could be a higher incidence of recurrences in
the corresponding short-term antibiotic arms.
Discussion
With our cohort in two embedded RCTs, we seek to
demonstrate clinically relevant noninferiority of a
shorter systemic antibiotic treatment in adult patients
with SI with and without implants [1] and, independ-
ently of the surgical drainage technique, the number of
debridements, underlying individual chronic immune
suppression, the infection localization, or the pathogens.
Importantly, all study participants will have accompany-
ing multidisciplinary surgical, re-educational, internist,
and infectious disease treatment and follow-up. We will
equally collect intraoperative soft tissues and bone for
future (laboratory) studies and assess adverse events,
overall costs, functional outcomes, and the dynamic
changes in nutritional status of the infected patients in
relation to their therapy and outcomes. The studies will
start in Zurich but are expandable to other study centers
with experience in treating SI.
The primary outcome is remission at the last follow-up,
but the RCT can be adjusted for different important vari-
ables, such as the number of surgical debridements, the
use of a negative pressure therapy, administration of a par-
enteral antibiotic regimen, or the total duration of anti-
biotic therapy. As in many fields of septic orthopedic
surgery, the number of surgical debridements does not
formally influence remission rates, which has been shown
for chronic osteomyelitis [10], septic native joint arthritis
[11], fracture device infections [12], infected open frac-
tures [11], or prosthetic joint infections [13]. There is very
little evidence to guide surgical treatment of patients who
require a single versus multiple debridements. Dipaola
et al. [14] developed a predictive model for spinal surgical
site infections based on 128 infected patients. Among 30
clinical variables analyzed, and despite the retrospective
nature of their analysis, they validated 4 variables as being
strongly predictive regarding the necessity of multiple de-
bridements: infection due to methicillin-resistant
Staphylococcus aureus, bacteremic disease, posterior lum-
bar spine, and use of nonautologous bone grafts.
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Certainly, the most important variables retrieved from
our trials will be antibiotic-related. Most author groups
advocate a minimum length of parenteral antibiotic
course of 2–4 weeks and a total duration up to 3 months
[15, 16] for SIs, although some groups recommend only
2 weeks of parental therapy [17, 18], or even only 2–3
days [19], without further compromising success. To cite
examples, Clark and Shufflebarger [20] treated delayed
infections with surgery and 48–72 h of parenteral antibi-
otics followed by 10 days of targeted oral antibiotics. All
infections were eradicated. Likewise, Richards and Emara
[21] prescribed systemic antimicrobials only for 3 weeks,
administered 2–5 days parenterally, followed by a 7 to
14 day-course of oral treatment.
In the entire field of orthopedic infections, there are no
formal scientific data proving the benefit of a systemic
antibiotic therapy beyond 6 weeks compared with 4–6
weeks or even less. Exceptions are by nature expert opin-
ions in previous book chapters or past publications with-
out their own database analyses or the therapy of special
microorganisms requiring long-lasting antibiotic therapies
such as mycobacteria [22], Nocardia spp. [23], and Actino-
myces or fungi [24]. To cite recent and our own examples
of investigations regarding the overall antibiotic duration,
sacral osteomyelitis [25], long-bone osteomyelitis [10],
fracture device-related infections [12], spondylodiscitis
[25], prosthetic joint infections [13], diabetic foot osteo-
myelitis [26, 27], and many more failed to enhance remis-
sion rates if antibiotics were prolonged beyond 4–6 weeks,
even in the presence of an infected implant. These emer-
ging and relatively short durations are equally acknowl-
edged by international consensus meetings [28] of
surgeons and infectious disease physicians who treat these
infections and perform research on them.
There are also studies with less than 6 weeks of total
antimicrobial therapy, especially in the pediatric litera-
ture on hematogenous osteomyelitis. In this particular
setting, a 3-week antibiotic course appears to be suffi-
cient, as highlighted by many authors [29–32]. Among
adults, 38 case series with antibiotic treatment durations
of 3–4 weeks, including 5 to 36 patients each, revealed
cure rates of approximately 80% according to a review
published in 2005 [33].
A second issue is the distinction between intravenous
and oral antibiotic administration, at least initially.
Current textbooks recommend the parenteral route for at
least the first 2 weeks for all osteoarticular infections [1,
34–36], but this recommendation is not evidence-based
either. There are no predictive clinical markers that would
justify prolonged initial intravenous administration. In
addition, up to one-third of patients with chronic bone
and implant infections may experience antibiotic-related
or catheter-related problems during parenteral treatment
[36]. For economic reasons as well as patient and nurse
comfort, parenteral administration should be kept to a
minimum [37]. Good bone penetration during parenteral
and oral administration has been proven in several reports
[38–40], and data suggest that an early switch to oral anti-
biotics is as effective as prolonged parenteral regimens
[41].
A Cochrane review investigated five trials comparing
oral vs. parenteral antibiotics in osteomyelitis. There was
no statistically significant difference between the two
groups in the remission rate 12 months or more after
treatment [42]. Glassman et al. successfully treated two
patients with SIs from the start with oral ciprofloxacin, an
antibiotic with excellent oral bioavailability and bone
penetration [43]. Even in cases of diabetic foot osteomye-
litis, a frequent disease with a hallmark of vascular insuffi-
ciency and tissue ischemia, there are no data indicating
the superiority of any particular route of delivery of sys-
temic antibiotics [44]. Byren et al. demonstrated that an
intravenous course of antibiotics for over 4 weeks did not
enhance cure for the treatment of arthroplasty infections
[45]. Zimmerli et al. summarized observational studies
that showed the same failure rates of arthroplasty infec-
tion treatment despite a prolonged period (4–6 weeks) of
intravenous treatment [46]. For the treatment of bone in-
fections, there are some antibiotics that have already been
proven to be effective in oral form. Quinolones, rifampi-
cin, co-trimoxazole, tetracycline, or clindamycin have such
a good and sufficient oral bioavailability [47].
Our future patient population will comprise all comor-
bidities and chronic immune suppressions. For example,
we expect 20–25% of patients will have diabetes [48] in
our center, along with other immune suppressions such
as cancer, advanced cirrhosis, and steroid medication.
While immune suppression (especially diabetes mellitus)
is an acknowledged independent risk associated with
healthcare-associated surgical site infections [49], its in-
fluence on remission during therapy for SIs is unknown.
Indeed, all current therapeutic concepts for osteoarticu-
lar infections in general do not rely on the presence or
absence of immune suppression [1, 10, 12, 25], suggest-
ing that surgical debridement and long antibiotic admin-
istration overcome eventual shortcomings of patients’
immunity. Although our SASI trials do not target the as-
sociation of immune suppression with SI outcomes, we
will see if immune suppression tends to decrease remis-
sion when we shorten the antibiotic duration.
Finally, our RCT will also give insight into the nutri-
tional status of patients with SI. Current literature is di-
vided between experts advocating a causal relationship
between malnutrition and occurrence of surgical site in-
fections in orthopedic surgery and others who have
retrospectively investigated this relationship and mostly
found no associations [50]. Both factions know even less
about the associations and the dynamics of nutritional
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status in already-infected orthopedic spine patients and
the association of these alterations with remission, func-
tional outcomes, and underlying immune suppression,
let alone the question of the benefits of nutritional inter-
ventions during the combined surgical, physiotherapeu-
tic, and antibiotic treatment [51]. This will be terra nova
that we embed into our trials.
We do not expect major difficulties in performing our
studies. Despite two prospective randomized designs (for
SI with and without implants) and only 236 different epi-
sodes anticipated, patients’ voluntary participation might
be low. Likewise, patients who continue to be treated out-
side of our center may be lost to follow-up or may have
their treatment changed because the follow-up physicians
do not agree. However, our center is the largest public
hospital for surgical SIs in the region, and it is a university
spine center, so this is unlikely to be a major bias. Last,
and formally, our study participants will benefit from an
initializing surgical debridement of infections. Hence, our
results will not be valid for the conservative treatment of
SI, which must not be confounded.
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